1.10
+0.05(+4.76%)
Currency In USD
Address
3675 Market Street
Philadelphia, PA 19104
United States of America
Phone
267 817 5790
Website
Sector
Healthcare
Industry
Biotechnology
Employees
152
First IPO Date
June 18, 2021
| Name | Title | Pay | Year Born |
| Mr. Brent Pfeiffenberger M.B.A., Pharm.D. | Chief Executive Officer & Director | 274,065 | N/A |
| Dr. Adrienne Farid Ph.D. | Chief Development Officer, CCO & Head of Early Development | 670,289 | 1962 |
| Dr. Gregory Russotti Ph.D. | Chief Technology & Manufacturing Officer | 852,564 | 1967 |
| Michael Naso Ph.D. | Senior Vice President of Cell Engineering | 0 | N/A |
| Ms. Katja Buhrer | SVice President, Head of Corporate Affairs & Strategy | 0 | 1982 |
| Dr. Shane Williams Ph.D. | Chief People Officer | 0 | N/A |
| Dr. Nick Trede M.D., Ph.D. | Senior Vice President & Head of Clinical Development | 0 | N/A |
| Mr. Kenneth J. Dow J.D. | Senior Vice President of General Counsel | 0 | N/A |
| Dr. Morgan Conn Ph.D. | Chief Financial Officer | 0 | 1969 |
| Dr. Chad A. Cowan Ph.D. | Chief Scientific Officer | 0 | N/A |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.